Home

Search

Pathway AI

Account ⋅ Sign Out

Table of contents

Nephrogenic systemic fibrosis

Key sources
The following summarized guidelines for the evaluation and management of nephrogenic systemic fibrosis are prepared by our editorial team based on guidelines from the European Academy of Dermatology and Venereology (EADV 2017).
1

Guidelines

1.Screening and diagnosis

Etiology: recognize that nephrogenic systemic fibrosis is an iatrogenic condition observed in patients with end-stage renal failure and is associated with gadolinium exposure.
E
Create free account

2.Medical management

Medical therapy: insufficient evidence to recommend any treatment in patients with nephrogenic systemic fibrosis.
I

3.Preventative measures

Avoidance of gadolinium-containing contrast agents
Avoid using high-risk gadolinium-based contrast agents, especially in patients with an eGFR of < 30 mL/min, for the prevention of nephrogenic systemic fibrosis.
D
Use a low-risk gadolinium medium and reduce the dose of the gadolinium-based contrast agents to the minimum effective dosage for imaging if MRI with gadolinium-based contrast agents is indispensable.
E

More topics in this section

  • Dialysis